Skip to main content

DEVELOPMENT PIPELINE

Explore our Active Programs

BRAIN-DRUG DELIVERY TECHNOLOGIES

Psycheceutical is currently developing products for neuropsychiatric and neurocognitive disorders which are at clinical and pre-clinical stages.

DEVELOPMENT PIPELINE

Our goal is to employ our patented brain-drug delivery strategies to clinically advance FDA-approved psychedelics and Generation 3 therapeutics for neuropsychiatric and neurocognitive disorders in the treatment of mental health and mood disorders.

PSY-007

KETAMINE
INDICATION:

Post Traumatic Stress Disorder (PTSD)

 

STAGE:

Phase I Clinical Trials

 

PSY-007

KETAMINE
INDICATION:

Complex Regional Pain Syndrome (CRPS)

 

STAGE:

CMC

 

PSY-034

UNDISCLOSED
INDICATION:

Addiction

 

STAGE:

CMC

 

PSY-058

UNDISCLOSED
INDICATION:

Parkinson’s Disease

 

STAGE:

Preclinical

 

Our additional IP uniquely focuses on development of brain-drug delivery to combat traumatic brain injuries as we seek to improve functional outcomes for those who suffer from TBI-related conditions.

PSY-311

UNDISCLOSED
INDICATION:

Traumatic Brain Injury (TBI)

 

STAGE:

CMC

 

PSY-322

UNDISCLOSED
INDICATION:

Traumatic Brain Injury (TBI)

 

STAGE:

Preclinical

 

PSY-345

UNDISCLOSED
INDICATION:

Traumatic Brain Injury (TBI)

 

STAGE:

Preclinical

 

Discover Our Drug

Delivery Technologies

PSY-007
Post Traumatic Stress Disorder (PTSD)

Market Opportunity:

  • In 2020, about 13 million Americans had PTSD
  • 6 out of every 100 U.S. adults (or 6%) will have PTSD in their lifetime
  • 7 out of every 100 Veterans (or 7%) will have PTSD in their lifetime
  • VA research estimates the annual economic burden of PTSD at $232 billion (2018)
  • The global market for PTSD drugs is expected to reach $26.1 billion by 2031

Technology:

  • Patented NeuroDirect™ technology
  • Provisional Patent of PSY-007 filed for PTSD
  • Novel delivery strategy of FDA-approved compound
  • 505(b)(2) IND-filing to expedite market access
  • Safe and accessible treatment option for PTSD
Explore The NeuroDirect™ Technology
PSY-007
Complex Regional Pain Syndrome (CRPS)

Market Opportunity:

  • CRPS affects nearly 200,000 U.S. patients annually
  • Impairs function, sleep, and activities of daily living
  • Associated with worsening depression, anxiety, and diminished quality of life
  • Current medications for CRPS have adverse side effects

Technology:

  • Patented NeuroDirect™ technology
  • Novel delivery strategy of FDA-approved compound
  • 505(b)(2) IND-filing to expedite market access
  • 7-year exclusivity
Explore The NeuroDirect™ Technology
PSY-034
Addiction

Market Opportunity:

  • 20.4 million Americans suffered from a substance use disorder (SUD) in 2019
    • 14.5 million people suffered from an alcohol use disorder
    • 8.3 million people suffered from an illicit drug use disorder 
    • 2.4 million people suffered from both
  • Research estimates the annual economic cost of SUD in the U.S. is approximately $3.73 Trillion
  • Global market for SUD treatment expected to reach $23.1 billion by 2031 

Technology:

  • Patented NeuroDirect™ technology
  • Novel delivery strategy to avoid side effects
  • Use for investigation and treatment of addiction
Explore The NeuroDirect™ Technology
PSY-058
Parkinson’s Disease

Market Opportunity:

  • Nearly one million people in the U.S. are living with Parkinson’s Disease (PD)
  • Nearly 90,000 people in the U.S. are diagnosed with PD each year
  • PD is the second-most common neurodegenerative disorder in the U.S.
  • Has no cure, only symptom relief with added side-effects
  • Global market for PD drugs expected to reach $10.4 billion by 2031

Technology:

  • Patented NeuroDirect™ technology
  • Patented PSY-058 for PD
  • Novel delivery strategy of FDA-approved compound to avoid side effects
  • 505(b)(2) IND-filing to expedite market access
Explore The NeuroDirect™ Technology
PSY-311
Traumatic Brain Injury (TBI)

Market Opportunity:

  • Over 5 million Americans suffer from a disability related to TBI
  • There were over 69,000 TBI-related deaths in the U.S. in 2021
  • 80% of TBI are mild and are often undiagnosed
  • No FDA-approved drugs for treating symptoms of mild TBI
  • Global market for TBI treatments is expected to reach USD 201.1 billion by 2029

Technology:

  • New chemical entity
  • Licensing agreements under negotiations
  • Use for investigation and treatment of TBI and the causes of neuroinflammatory pathology
PSY-322
Traumatic Brain Injury (TBI)

Market Opportunity:

  • Over 5 million Americans suffer from a disability related to TBI
  • There were over 69,000 TBI-related deaths in the U.S. in 2021
  • 80% of TBI are mild and are often undiagnosed
  • No FDA-approved drugs for treating symptoms of mild TBI
  • Global market for TBI treatments is expected to reach USD 201.1 billion by 2029

Technology:

  • New chemical entity
  • Licensing agreements under negotiations
  • Use for investigation and treatment of TBI and the causes of neuroinflammatory pathology
PSY-345
Traumatic Brain Injury (TBI)

Market Opportunity:

  • Over 5 million Americans suffer from a disability related to TBI
  • There were over 69,000 TBI-related deaths in the U.S. in 2021
  • 80% of TBI are mild and are often undiagnosed
  • No FDA-approved drugs for treating symptoms of mild TBI
  • Global market for TBI treatments is expected to reach USD 201.1 billion by 2029

Technology:

  • Novel indication of an FDA-approved compound
  • 505(b)(2) IND-filing to expedite market access
  • Use for Investigation and treatment of TBI and the causes of neuroinflammatory pathology